BRCA2 and familial pancreatic carcinoma: Moreover, characterization of cisplatin and Poly(ADP-ribose) polymerase inhibitor (PARPi) resistant BRCA2-mutant breast (HCC1428) and pancreatic cancer cell line (Capan-1), along with patient tumors, has revealed revertant variants in BRCA2 that restores, in cis, the open reading frame encoding two BRC repeats15.